Key Documents

View All Documentation

SML1586

Oritavancin diphosphate

Name: Oritavancin diphosphate
Brand: SIGMA

98.0% ~ 102.0% (HPLC)

Synonym(s):

LY333328 diphosphate, (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3"-[(4′-chloro[l,1′-biphenyl]-4-yl)methyl]vancomycin diphosphate, LY-333328

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₈₆H₉₇Cl₃N₁₀O₂₆ · 2H₃PO₄

CAS Number:

192564-14-0

Molecular Weight:

1989.09

UNSPSC Code:

12352200

NACRES:

NA.77

Assay:

98-102% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Oritavancin diphosphate, 98-102% (HPLC)

Quality Level

100

assay

98-102% (HPLC)

form

powder

color

white to off-white

storage temp.

2-8°C

SMILES string

[P](=O)(O)(O)O.[P](=O)(O)(O)O.Clc1ccc(cc1)c2ccc(cc2)CN[C@@]3([C@H]([C@@H](O[C@H](C3)O[C@H]4[C@@H](O[C@@H]([C@H]([C@@H]4O)O)CO)Oc5c6cc7cc5Oc8c(cc(cc8)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]7C(=O)N[C@@H]9c%10cc(c(cc%10)O)c%11c(cc(cc%11O)O)[C@H](NC(=O)[C@@H](NC9

InChI

1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1

InChI key

PWTROOMOPLCZHB-BHYQHFGMSA-N

Description

Biochem/physiol Actions

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days.

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens.

Disclaimer

category 1 skin sensitizer

pictograms

GHS07

signalword

Warning

hcodes

H317

pcodes

P261 - P272 - P280 - P302 + P352 - P333 + P313 - P362 + P364

Hazard Classifications

Skin Sens. 1A

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000457086

0000457085